1037.3000 -10.55 (-1.01%)
NSE Sep 19, 2025 15:31 PM
Volume: 1.1M
 

logo
Zydus Lifesciences Ltd.
20 Nov 2017, 12:00AM
1037.30
-1.01%
Axis Direct
Cadila's Q2 EBITDA (+67% YoY, 22% above our estimate) was driven by gLialda (~USD 80-90 mn in our view) in US. EBITDA margin was up 520 bps YoY/1,405 bps QoQ at 26.5% on positive operating leverage, as India sales also grew 9% YoY. PAT at Rs 5.03 bn was in line with estimates on higher tax expense..
Zydus Lifesciences Ltd. is trading above all available SMAs
More from Zydus Lifesciences Ltd.
Recommended